Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Upsher-Smith Laboratories has purchased UK-based Proximagen Group, a developer of novel therapeutics for diseases of the central nervous system (CNS) and inflammation.
Subscribe to our email newsletter
Proximagen’s pipeline includes many programs which are in various stages of development across a number of therapeutic classes including CNS, inflammation, oncology and ophthalmology.
The acquisition will enable Upsher-Smith to research and develop pending programs of Proximagen, thus facilitating for its future growth.
Upsher-Smith president and chief executive officer Mark Evenstad said the acquisition of Proximagen adds significantly to the company’s scientific capabilities and supports the acceleration of its vision of becoming a leader in the CNS category.
"The combination of Upsher-Smith’s clinical development and commercialization expertise with Proximagen’s research and development platform provides the opportunity to further enhance our ability to bring new therapies to market to benefit patients," Evenstad added.